查詢結果分析
相關文獻
- PD-L1抑制劑--Atezolizumab用於晚期轉移性NSCLC
- A Novel Experience of Nivolumab-Associated Toxic Epidermal Necrolysis in a Patient with Metastatic Non-Small Cell Lung Cancer in Taiwan--A Case Report
- 非小細胞肺癌免疫療法藥物簡介
- Pembrolizumab於非小細胞肺癌之療效
- 非小細胞肺癌術前輔助性化學治療的經驗
- Molecular Mechanisms of Allergen-Specific Immunotherapy for Atopic Diseases
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- 非小細胞肺癌的治療
- 肝癌之非外科治療
頁籤選單縮合
| 題 名 | Pembrolizumab於非小細胞肺癌之療效=Efficacy of Pembrolizumab in Non-small-cell Lung Carcinoma |
|---|---|
| 作 者 | 何振珮; | 書刊名 | 藥學雜誌 |
| 卷 期 | 34:3=136 2018.09[民107.09] |
| 頁 次 | 頁73-78 |
| 分類號 | 418.29 |
| 關鍵詞 | 免疫療法; 非小細胞肺癌; Pembrolizumab; Immunotherapy; Non-small-cell lung carcinoma; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 免疫檢查點抑制劑 (immune checkpoint inhibitor) 是癌症免疫療法 (immunotherapy) 的新趨勢。而 pembrolizumab 為 programmed death 1 (PD-1) 免疫檢查點抑制劑,用於 治療非小細胞肺癌 (non-small-cell lung carcinoma)。Pembrolizumab 相較於化學治療、 放射治療或標靶藥物治療,已發現顯著延長非小細胞肺癌病人的療效反應率、癌症無 惡化存活期與存活率,並有較佳的藥物安全性。因此,pembrolizumab 不僅是非小細 胞肺癌治療發展的新希望,也帶給了非小細胞肺癌病人一種治療新選擇。 |
| 英文摘要 | The immune checkpoint inhibitors of immunotherapy for cancers have become a crucial modality for carcinoma treatment. Pembrolizumab (Keytruda), a programmed death 1 (PD- 1) immune checkpoint inhibitor, has exhibited many beneficial effects in immunotherapy for non-small-cell lung carcinoma. It has significantly increased the response rate, progressionfree survival and survival rate with better drug safety compared to those of chemotherapy, radiotherapy or targeted therapies in patients with non-small-cell lung carcinoma. Pembrolizumab, is a highly expected option for treating patients with non-small-cell lung carcinoma. |
本系統中英文摘要資訊取自各篇刊載內容。